ETR:SBSStratec Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Stratec SE Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add €93.70 -0.30 (-0.32 %) (As of 07/14/2020 12:32 PM ET) Add Compare Share Today's Range€90.60Now: €93.70▼€95.3050-Day Range€76.70MA: €83.03▼€94.4052-Week Range€46.40Now: €93.70▼€96.80Volume24,237 shsAverage Volume6,253 shsMarket Capitalization$1.13 billionP/E Ratio66.41Dividend Yield0.89%BetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsHeadlinesOptions Chain Stratec SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates through three segments: Instrumentation, Diatron, and Consumables. The Instrumentation segment designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Consumables segment develops and sells scientific materials, such as nucleic acid purification; and designs and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technology. Stratec SE also develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.Read More Beat the Market (BTM) Rank™ 1.4 Analyst's Opinion Consensus RatingStratec has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of €85.25, Stratec has a potential downside of 9.0% from its current price of €93.70.Amount of Analyst CoverageStratec has only been the subject of 3 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesStratec has received 140 “outperform” votes. (Add your “outperform” vote.)Underperform VotesStratec has received 109 “underperform” votes. (Add your “underperform” vote.)Community SentimentStratec has received 56.22% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Stratec and other stocks. Vote “Outperform” if you believe SBS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SBS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.8 Dividend Strength Dividend YieldStratec has a dividend yield of 0.89%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthStratec does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Stratec is 59.53%. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stratec insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Stratec is 66.41, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Stratec is 66.41, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.84.Price to Book Value per Share RatioStratec has a P/B Ratio of 7.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.4Community Rank: 2.8Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.00 out of 5 stars Industry, Sector and Symbol Stock Exchange ETR Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolETR:SBS Previous Symbol CUSIPN/A CIKN/A Webwww.stratec.com Phone+49-7082-79160Debt Debt-to-Equity Ratio66.24 Current Ratio3.67 Quick Ratio2.25Price-To-Earnings Trailing P/E Ratio66.41 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$231.58 million Price / Sales4.87 Cash Flow€2.83 per share Price / Cash Flow33.13 Book Value€13.11 per share Price / Book7.15Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees1,158 Outstanding Shares12,025,300Market Cap$1.13 billion Next Earnings Date8/13/2020 (Estimated) OptionableOptionable SBS Rates by TradingView Receive SBS News and Ratings via Email Sign-up to receive the latest news and ratings for SBS and its competitors with MarketBeat's FREE daily newsletter. Stratec (ETR:SBS) Frequently Asked Questions How has Stratec's stock been impacted by COVID-19 (Coronavirus)? Stratec's stock was trading at €64.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SBS stock has increased by 46.4% and is now trading at €93.70. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Stratec? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stratec in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Stratec. When is Stratec's next earnings date? Stratec is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Stratec. What price target have analysts set for SBS? 4 brokers have issued 1-year price targets for Stratec's stock. Their forecasts range from €69.00 to €97.00. On average, they expect Stratec's share price to reach €85.25 in the next twelve months. This suggests that the stock has a possible downside of 9.0%. View analysts' price targets for Stratec. Has Stratec been receiving favorable news coverage? News articles about SBS stock have trended somewhat negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Stratec earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Stratec. Who are some of Stratec's key competitors? Some companies that are related to Stratec include ConvaTec Group (CTEC), Avita Medical (AVH), Zynex (ZYXI), Draegerwerk AG & Co KGaA (DRW3), Creo Medical Group (CREO), Avacta Group (AVCT), Hamilton Thorne (HTL), Imricor Med SYS Cdi 1:1 US Person Prohibited Excluding QIB (IMR), Medica Group (MGP), Electromed (ELMD), Electromed (ELMD), Cyclopharm (CYC), Patient Home Monitoring (PTQ), Titan Medical (TMD) and Advanced Oncotherapy (AVO). View all competitors. What other stocks do shareholders of Stratec own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stratec investors own include Great Portland Estates (GPOR), Gogo (GOGO), Depomed (DEPO), Cenovus Energy (CVE), China Hydroelectric Co. (USD) (CHC), Bio-Rad Laboratories (BIO), Berkshire Hills Bancorp (BHLB), ASGN (ASGN), Apptio (APTI) and Anadarko Petroleum (APC). Who are Stratec's key executives? Stratec's management team includes the following people: Mr. Marcus Wolfinger, Chairman of Board of Management & CEO (Age 52)Dr. Robert Siegle, Director of Fin. & HR and Member of Board of Management (Age 52)Dr. Claus Vielsack, Director of Product Devel. & Member of Board of Management (Age 52)Mr. Hermann Leistner, Founder & Advisor (Age 73)Sandra Eberle, Head of Investor Relations What is Stratec's stock symbol? Stratec trades on the ETR under the ticker symbol "SBS." What is Stratec's stock price today? One share of SBS stock can currently be purchased for approximately €93.70. How big of a company is Stratec? Stratec has a market capitalization of $1.13 billion and generates $231.58 million in revenue each year. Stratec employs 1,158 workers across the globe. What is Stratec's official website? The official website for Stratec is www.stratec.com. How can I contact Stratec? Stratec's mailing address is Gewerbestr. 37, BIRKENFELD, 75217, Germany. The company can be reached via phone at +49-7082-79160. This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
